About MedImmune

Overseeing global operations at MedImmune is a highly respected team of industry leaders. Our robust portfolio of research projects and clinical product candidates now incorporates the biologics assets of AstraZeneca and those of Cambridge Antibody Technology.

Bahija Jallal

Bahija Jallal, Ph.D.

Executive Vice President, AstraZeneca
Head of MedImmune

About Bahija

Dr. Bahija Jallal is Executive Vice President of AstraZeneca and head of MedImmune, a global biologics research and development organization with locations in Gaithersburg, California and Cambridge, UK.  She is a member of the senior executive team at AstraZeneca reporting to the CEO. Dr. Jallal joined MedImmune in March 2006.

Dr. Jallal is passionate about leading and shaping MedImmune’s rich pipeline of drugs targeting cancer, infections, respiratory and inflammatory diseases, cardio-vascular and metabolic diseases and pain to ultimately develop new medicines for patients.

Dr. Jallal is a member of the Board of Directors of the University of Maryland Health Sciences Research Park Corporation, a non-profit organization that manages biomedical research development at the BioPark. She was recently appointed to the Board of Trustees of The Johns Hopkins University.

Dr. Jallal has authored over 70 peer-reviewed publications and has over 15 patents. She is a member of the American Association of Cancer Research, the American Association of Science and the Pharmacogenomics Working Group. She serves as a member of the Board of Directors for the Association of Women in Science and an advisory board member of the Healthcare Business Women’s Association. She was named one of FierceBiotech’s "Women in Biotech" and a "Women Who Mean Business" from the Washington Business Journal. In 2013, Dr. Jallal earned the Grace Award from Cancer Research Institute.

Prior to joining MedImmune, Dr. Jallal worked with Chiron Corporation where she served as vice president, drug assessment and development, and successfully established the company’s translational medicine group.  Prior to Chiron Corporation, she worked at Sugen, Inc. where she held positions of increasing responsibility leading to senior director, research.

Dr. Jallal received a master’s degree in biology from the Universite de Paris VII in France, and her doctorate in physiology from the University of Pierre & Marie Curie in Paris. She conducted her postdoctoral research at the Max-Planck Institute of Biochemistry in Martinsried, Germany.

Matt Bell

Matt Bell, Ph.D.

Chief Operating Officer

About Matt

Dr. Bell joined MedImmune in January 2010. Before being named Chief Operating Officer for MedImmune in March, 2013, Dr. Bell served as a special advisor to AZ CEO Pascal Soriot and led the recently announced AstraZeneca strategy review. As MedImmune COO, Dr. Bell oversees R&D-enabling functions including IS/informatics, site and business operations, project management, and R&D training. 

When he joined MedImmune, Dr. Bell established the global R&D operations and strategy function, which brought together three decentralized groups and 175 staff members into global functional lines for the first time in the research and development area. 

Dr. Bell joined MedImmune from Wyeth, where for 7 years, he helped to shape the growth of the research biologics capability and strategy. He led the deal team for a $100 million translational medicine partnership with the Universities of Scotland and was closely involved in the establishment of a major offshore chemistry partnership with GVKBio.

Dr. Bell holds a Double First Class Degree, Natural Sciences (Part II Pharmacology) from the University of Cambridge, England and a Ph.D. in Neuorpharmacology from the University of Cambridge. 

Ed Bradley

Edward Bradley, M.D.

Senior Vice President, R&D
Oncology iMED Head

About Edward

Edward Bradley is Senior Vice President and Head of the Oncology Innovative Medicines unit (iMED) at MedImmune. As iMED head, he leads the cross-functional teams responsible for the  strategy, growth, and advancement of the oncology portfolio. 

Dr. Bradley joined MedImmune in August 2010, as Vice President, Clinical Development, Oncology.   Dr. Bradley, a board-certified medical oncologist, earned his medical degree and completed his medical residencies at Harvard. He conducted his clinical oncology training in the Medicine Branch of the National Cancer Institute and was a fellow in Robert Gallo’s laboratory.  He returned to the Harvard faculty as Director, Laboratory of Tumor Cell Biology in the Beth Israel- Brigham and Women’s Hospital, and has maintained a career-long involvement in immunologically focused therapies for cancer.  

As head of oncology for CETUS, he led the development and registration of interleukin-2 (ProLeukin) for renal cell carcinoma.  He initiated and led Sterling Oncology and the Sterling-Winthrop Immunoconjugates Division, a subsidiary of Eastman-Kodak and initiated the US development of oxaliplatin (Eloxatin) following its acquisition by Sanofi.  He has held other significant pharmaceutical development positions, including Head of Medical Sciences and Development for DuPont Pharmaceutical, Chief Medical Officer. USA, and global head of medical imaging development for Schering AG. Prior to joining MedImmune, Dr. Bradley was Vice President and Head, Oncology Development at Incyte and conducted the registration trials for ruxolitinib ( Jakafi.) 

Dr. Bradley has served as Chief Scientific Officer for an early-stage biotechnology company, has led successful clinical development programs in non-oncology areas, including efavirenz (Sustiva), tinzaparin (Innohep) and the US registration of clopidogrel (Plavix) and the imaging agent Definity.   He has served on pharma sector scientific advisory boards, editorial review boards, and has authored over 50 peer-reviewed publications in the medical oncology area. 

David Berman

David Berman, M.D., Ph.D.

Senior Vice President, R&D
Oncology iMED Head

About David

David Berman is Senior Vice President and Head of the Oncology Innovative Medicines unit (iMED) at MedImmune. As iMED head, he leads the cross-functional teams responsible for the strategy, growth, and advancement of the oncology portfolio. Dr. Berman sit’s on AstraZeneca’s Cancer Enterprise team working closely with his small-molecule, GMD and GPPS colleagues.

Prior to joining MedImmune, Dr. Berman was Vice President and Head of the Immuno-Oncology Exploratory Development Team at Bristol Meyers Squibb and held various leadership roles in early and late-stage clinical development of the oncology portfolio after he joined in 2005. Dr. Berman was an attending pathologist at the National Cancer Institute of the National Institute of Health. A graduate of Massachusetts Institute of Technology, David earned his Ph.D. in the laboratory of Dr. Alfred Gilman at the University of Texas Southwestern Graduate School and his M.D. from the University of Texas Southwestern Medical School. He completed his residency in anatomic pathology at the National Cancer Institute and was pathology fellow at The Johns Hopkins Hospital.

Dr. Berman is a widely published author with more than 40 journal articles.

Jim Brady

Jim Brady, MBA, CPA, CFE

Vice President, Finance

About Jim

Jim Brady, MBA, CPA, is MedImmune’s Vice President of Finance. With over twenty-five years of diverse business experience, he has worked in a number of increasingly senior roles across AstraZeneca, becoming recognized for his knowledge, strong team leadership skills and commitment to people development.

Jim began his AstraZeneca career in the Internal Audit Group where he became the Operational Audit Manager for North America before being appointed Controller of a subsidiary company of our US business. Jim then moved into Operations as the Site Controller at the Newark Delaware Production Site before moving back to the US commercial business where he was appointed the Director of Finance for US Government, Policy and Managed Markets and then the US Finance Director for Crestor and the Emerging Brands Portfolio. Jim then worked in Global Marketing where he held the role of Executive Director of Finance. More latterly, Jim returned to the Internal Audit Group as the Chief Audit Executive for AstraZeneca. Most recently, he was the Regional Commercial Finance Director for Asia Pacific.

Before joining AstraZeneca, Jim worked at Arthur Andersen & Company where he received his accountancy training and qualified as a Certified Public Accountant.

Jim received his B.A. in Accounting from Saint Joseph University and holds a dual MBA in Finance and Marketing from Drexel University.

Iain Chessell

Iain Patrick Chessell, Ph.D.

Vice President, R&D
Neuroscience iMED Head

About Iain

Dr. Iain Chessell is the Head of the Neuroscience effort at MedImmune, leading a cross-functional team dedicated to and advancement of the IMED’s large molecule neuroscience portfolio.

Dr. Chessell joined MedImmune in November 2008 as vice president, Research. In this role, he was responsible for overseeing MedImmune’s preclinical programs, including those targeting pain control (analgesia) and neurodegenerative diseases such as Alzheimer’s disease. In 2010 he was promoted to vice president and head of the Neuroscience Center of Excellence (CoE). 

Prior to joining MedImmune, Dr. Chessell was chief executive officer at NeuroDiscovery where he completed a number of Phase 1 and Phase 2 clinical programs, and restructured a parallel revenue business to maximise profitability and efficiency. Previously, Dr. Chessell was worldwide head of pain research for GlaxoSmithKline, where he delivered eight clinical candidates in the period 2004-2007, and was involved in multiple clinical development projects from Phase 1 to Phase 3. He was also responsible for review of potential in-license opportunities, and was chair of the core disease teams for pain and neurodegeneration, as well as serving as chair of the Neurology Centre of Excellence for Drug Discovery (CEDD) management team. Dr. Chessell also managed several high profile academic and industrial collaborations, and is author of more than 80 peer reviewed publications. 

Dr. Chessell received his bachelor’s degree in pharmacology from University College London, where he graduated first class with honours. He received his doctoral degree from the Department of Neurochemistry at the Institute of Neurology, London. 

Gail Wasserman

Gail Folena-Wasserman, Ph.D.

Senior Vice President, Biopharmaceutical Development

About Gail

Dr. Gail Folena-Wasserman is the Head of Biopharmaceutical Development at MedImmune, and has oversight of all analytical, process, formulation and drug product development including delivery and devices; and clinical manufacturing and quality control for clinical products. Dr. Folena-Wasserman is responsible for research support, early and late-stage development, clinical manufacturing phases I-III, technology transfer and life cycle management.

She joined MedImmune in 1991 as director, development, and was promoted to vice president, development, in October 1995. In 2010, she was appointed head of vaccines and biologics development. Dr. Folena-Wasserman established the Biopharmaceutical Development (BPD) function and Clinical Manufacturing Capabilities (CMC) at MedImmune. Following the MedImmune acquisition by AstraZeneca, she led the transition from three development divisions (AZ biologics, Cambridge Antibody Technology, MedImmune) to the current biopharmaceutical development organization. 

Prior to joining the company, Dr. Folena-Wasserman spent nine years in natural products isolation and biopharmaceutical process development at SmithKline Beecham Pharmaceuticals. She holds four patents.

PharmaVOICE selected Dr. Folena-Wasserman as one of the 100 Most Inspiring People in 2011.

Dr. Folena-Wasserman holds a bachelor’s degree in biology and chemistry from Montclair State University in New Jersey, and received a master’s degree in biochemistry and a doctorate in chemistry from The Pennsylvania State University.

Jamie Freedman

Jamie Freedman, M.D., Ph.D.

Senior Vice President, Clinical Development

About Jamie

Jamie Freedman MD, PhD is Medimmune’s Head of Clinical Development, leading clinical development activities. As a physician-scientist, he offers hands-on experience of both early and late drug development of small molecule and biopharmaceutical products in biotech and large pharmaceutical companies. 

Immediately prior to joining MedImmune, Jamie was at GlaxoSmithKline (GSK) where he served as Vice President, Oncology R&D. Before working at GSK, he headed up R&D at OPKO Health, a US-based multinational company specializing in pharmaceuticals, vaccines and diagnostic products. Prior to his role at OPKO Health, he held several leadership positions, including president and CEO and chief medical officer at Locus Pharmaceuticals, a private biotechnology company focused on the discovery and development of novel computationally designed drugs. He’s also held several leadership roles at Merck including clinical pharmacology, clinical oncology and experimental medicine for multiple therapeutic areas.

An extremely active professional, Jamie is board certified in Internal Medicine, Hematology and Medical Oncology and is a member of the American Society of Hematology and the American Society of Clinical Oncology. Jamie remains active in clinical practice, thus maintaining access to important clinical insights throughout his career. He is author of more than 20 peer-reviewed papers and holds three patents. 

Jamie received his undergraduate degree in biochemistry at McGill University and earned his MD and PhD at Tufts University, completing his internship and residency in Internal Medicine at the University of California, San Francisco. Jamie also completed a Fellowship in Hematology and Oncology at Harvard University.

Yong-Jun Liu

Yong-Jun Liu, M.D., Ph.D.

Senior Vice President, R&D
Head of Research

About Yong-Jun

Dr. Yong-Jun Liu has been appointed head of research for MedImmune, the global biologics research and development organization for AstraZeneca. He joined MedImmune in January, 2014.

Dr. Liu came to MedImmune from the Baylor Research Institute where he served as Vice President and Chief Scientific Officer and Director of the Baylor Institute for Immunology Research.

In his new role at MedImmune, Dr. Liu is responsible for driving pre-clinical research in multiple therapeutic areas to help advance drug candidates from discovery to development.

Dr. Liu has extensive translational research experience and is one of the most prolific researchers in immunology globally, with more than 230 published articles in top journals such as Nature, Science, Cell and the Journal of Experimental Medicine. His research has led to the development of several drug targets such as TSLP, OX40, ILT7 and pDC in the areas of allergy, autoimmune and cancer.

Dr. Liu is a graduate of the Norman Bethune University School of Medicine in China and the University of Birmingham in the United Kingdom. He spent 12 years at Schering-Plough in France, and DNAX Research Institute in California. Dr Liu was recruited by the University of Texas MD Anderson Cancer Center in 2002, where he was founding director of the Cancer Immunology Research Institute. He also served as the Chair of the Department of Immunology, building the nation’s leading immunology program as judged by top publications and grants.

Jane Osbourn

Jane Osbourn, Ph.D.

Vice President, R&D BioSuperiors
Site Leader; MedImmune Cambridge (UK)

About Jane

Jane Osbourn, PhD, is VP Research and Development for MedImmune's biosuperiors portfolio, as well as R&D Site Leader of MedImmune’s Cambridge, UK-based site.

Jane is a phage and ribosome display expert with significant experience in antibody engineering and drug discovery, and has generated several key publications and patents. She joined MedImmune, formerly Cambridge Antibody Technology (CAT), in September 1993 and initially focused on building large phage antibody libraries. Jane then worked within antibody generation teams, subsequently leading CAT’s technology development and making a significant contribution to the company’s research capabilities. From 2005 to 2007 she managed CAT’s oncology portfolio. Following the integration with MedImmune in 2007 Jane led the Research Department at the Cambridge site, becoming Site Leader for MedImmune Cambridge in July 2008. Additionally, after a period as Centre of Excellence leader within MedImmune’s cardio-vascular/metabolic disease team, in March 2011 Jane took on the leadership of new opportunities and is now managing the biosuperiors portfolio.

Prior to joining CAT, Jane completed a PhD at the John Innes Centre for Plant Science Research in Norwich, focusing on plant responses to viral infections. This was followed by a post doctoral position at Rutgers University, New Jersey in plant virology. She then moved into medical research, taking a British Heart Foundation Post Doctoral Fellowship to study the regulation of gene expression in smooth muscle cells at the Department of Medicine at Addenbrooke's Hospital in Cambridge.  Jane obtained a First Class degree in Natural Sciences (Biochemistry) from the University of Cambridge, where she also earned the Mosseri Prize for academic achievement in Biological Sciences. 

In 2010 Jane won the Institute of Directors’ East of England Business Woman of the Year Award in recognition of her contribution to the successful integration and development of CAT and MedImmune in Cambridge.

Jane is a member of the UK Medical Research Council Industry Grant award assessment panel and a member of the board of the UK BioIndustry Association (BIA). She is also an editor of both Mab Journal and Protein Engineering Design and Selection. 

Steve Projan

Steve Projan, Ph.D., FAAM

Senior Vice President, R&D
Infectious Diseases & Vaccines iMED Head

About Steve

Dr. Steve Projan is the Head of Infectious Diseases & Vaccines Innovative Medicines unit (iMED) at MedImmune, leading a cross-functional team dedicated to the therapeutic area strategy, prioritization and advancement of the company’s infectious disease and vaccine portfolio.

Dr. Projan joined MedImmune in 2010 as senior vice president of research and development and head of the Infectious Diseases & Vaccines iMED. 

Prior to joining MedImmune, Dr. Projan served as vice president and global head of Infectious Diseases at Novartis. He previously spent 15 years at Wyeth in roles of increasing responsibility with his last post as vice president and head of Biological Technologies. During his time at Wyeth, Dr. Projan started the Biologics Discovery Group (covering all therapeutic areas) and initiated multiple collaborations and partnerships, most notably with Cambridge Antibody Technology (now a part of MedImmune/AZ).  Prior to Dr. Projan’s work in the industry, he spent 14 years at the Public Health Research Institute and presently has over 110 publications to his credit.  

Dr. Projan received a bachelor of science from the Massachusetts Institute of Technology and masters of arts and philosophy in biological sciences and a doctorate in molecular genetics from Columbia University.

Cristina Rondinone

Cristina Rondinone, Ph.D.

Vice President, R&D
Cardiovascular/Metabolic Diseases iMED Head

About Cristina

Dr. Cristina Rondinone is the Head of Cardiovascular/Metabolic Disease Center (CV/MD) Innovative Medicines unit (iMED) at MedImmune, leading a cross-functional team dedicated to the therapeutic area strategy, prioritization and advancement of the company’s CV/MD portfolio.

Dr. Rondinone joined MedImmune in March 2011 as vice president, research & Development, Cardiovascular/Metabolic Diseases. Most recently, Dr. Rondinone served as Head of Metabolic and Vascular Diseases at Hoffmann-La Roche, Inc., where she led drug discovery research for the Metabolic Disease therapeutic area, including diabetes, dyslipidemia, cardiovascular and renal diseases, resulting in a number of compounds and biologics advancing into clinical trials. Dr. Rondinone spent five years at Hoffmann-la Roche in positions of increasing responsibility. Prior to Hoffmann-La Roche, Dr. Rondinone spent six years at Abbott laboratories where she served as Group Leader, Associate Research Fellow and Research Investigator. 

Dr. Rondinone’s other experience includes working as an Associate Professor in Molecular Medicine at the Department of Internal Medicine at University of Goteborg in Sweden; serving as a Visiting Fellow at the National Institute of Health in the Laboratory of Cellular and Development Biology and the Laboratory of Theoretical and Physical Biology and serving as a Teaching Instructor at the Department of Biological Sciences at Buenos Aires University. 

Dr. Rondinone brings more than 20 years industry and academia experience in Metabolic Diseases to MedImmune. In addition, she is the author of over 60 peer-reviewed scientific publications and is the author of two books. She is the co-inventor of three granted patents and applications. Dr. Rondinone is the recipient of numerous awards including being nominated and inducted as a Member of the Royal Academy of Pharmacy and Biochemistry in Spain (2010). 

Dr. Rondinone received her Ph.D. in Biological Sciences from Buenos Aires University and did her Postdoctoral research at the National Institutes of Health in Bethesda, Maryland. 


Tracy Rossin

Head of Corporate Affairs

About Tracy

Tracy Rossin is the Head of Corporate Affairs at MedImmune, the global biologics research and development arm of AstraZeneca, managing the company’s communications functions. Rossin has nearly two decades of communications experience, nine of which have been with AstraZeneca and MedImmune.

Rossin is responsible for brand and reputation management, internal and external communications, social media, executive engagement, corporate citizenship and community relations. She is a member of the MedImmune Leadership Team and the AstraZeneca Global Corporate Affairs Leadership Team.

Prior to this role, Rossin served as the External Communications Director at MedImmune, positively shaping perceptions of the company by leveraging its compelling science and robust pipeline, which accounts for approximately 50% of the overall AstraZeneca pipeline. She developed external communications strategies and supporting media plans for strategic business development deals, key pipeline developments and data milestones, including those in immuno-oncology. Rossin also established a media-based speaking engagement bureau and oversaw the company’s digital assets, including the corporate Web site, Twitter feed and the company blog, BioLogical.

Rossin began her tenure at AstraZeneca in 2006 and held multiple U.S. and global communications roles, including two international assignments (Belgium and Sweden) for key therapeutics across AstraZeneca’s portfolio. Before joining AstraZeneca, she held various positions at global public relations agencies working with corporate and healthcare related clients.

Rossin received a bachelor’s degree in political science and speech communication with a concentration in public relations from Miami University in Oxford, Ohio.

Reg Seeto

Reg Seeto, M.D.

Vice President,
Head of Partnering and Strategy

About Reg

Dr. Seeto rejoined the MedImmune Leadership Team (MLT) in 2013 to lead the Partnering and Strategy Group. He is responsible for MedImmune’s Business Development and Strategy teams that will deliver our external partnership strategy including academic collaborations, licensing of innovative assets and technologies and government alliances/partnerships and for all therapy area strategies. 

During 2011-12 Dr. Seeto was on an expatriate assignment as the President of AstraZeneca Thailand, where he was the first MedImmune executive to participate in a talent exchange and development program with AstraZeneca. Under his leadership, Thailand achieved its sales targets for the first time in 5 years and was awarded the RVP Award for Leadership for management of the country’s worst floods in more than half a century. 

Dr. Seeto originally joined MedImmune in 2008 as the Vice-President of Global Strategic Marketing and Portfolio Management where he worked closely with the R&D leadership team.  He was later promoted to the MedImmune Executive Team (MET) and established the Corporate Development and Strategy Group. 

Prior to MedImmune, Dr. Seeto was Vice President of Global Marketing for Schering Plough/Organon Biosciences and Executive Director of US Marketing for Boehringer Ingelheim Pharmaceuticals. Earlier in his career he was a consultant at McKinsey & Company and started his career as a medical doctor involved in both clinical practice and research. He has also published first author publications in peer reviewed journals. 

Dr. Seeto holds his medical degree (with honors) from the University of Sydney, Australia.

Bing Yao

Bing Yao, Ph.D.

Senior Vice President, R&D
Respiratory, Inflammation & Autoimmunity
iMED Head

About Bing

Dr. Zhengbin (Bing) Yao is the Head of the Respiratory, Inflammation & Autoimmunity (RIA) Innovative Medicines unit (iMED) at MedImmune, leading a cross-functional team dedicated to the therapeutic area strategy, prioritization and advancement of the company’s RIA portfolio.

Dr. Yao joined MedImmune in 2010 as senior vice president of research and development and head of the RIA iMED. He initiated the MEDI-Wuxi joint venture and he currently serves on its Joint Development Committee. He also co-chairs the MedI/AstraZeneca-Amgen collaboration.

Bing is credited with the discovery of human interleukin 17 and interleukin 17 receptor. His work on interleukin 17 has been selected as a "Pillar of Immunology" by a panel of world-renowned immunologists on behalf of the American Association of Immunologists.

An accomplished executive and scientist with more than 18 years of experience in the biotechnology and pharmaceutical industry, Dr. Yao most recently led the project team leaders (PTL) group for immunology, neurosciences, virology and metabolism for Genentech. He previously served as vice president of Research, acting head of clinical and Corporate Officer for Tanox and held other key roles at Aventis, and Amgen. 

Dr. Yao received his doctorate in microbiology and immunology from the University of Iowa and did his postdoctoral work at Immunex. In addition, Dr. Yao has over 20 granted patents and applications and has more than 50 peer-reviewed scientific publications to his name. 

MedImmune Careers

Search the latest career opportunities at MedImmune, read about our culture and diversity, and more.

Read more
Our Culture our culture

Learn about MedImmune’s unique company culture and the people who make it happen.

Read more